Completed PHASE2 INTERVENTIONAL NCT00165659

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Sponsor: Eisai Limited

Updated 6 times since 2017 Last updated: Jan 28, 2010 Started: Nov 30, 2002 Primary completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00165659, this PHASE2 trial focuses on Alzheimer Disease and remains completed. Sponsored by Eisai Limited, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Nov 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eisai Limited

Data source: Eisai Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aio, Japan , Akita, Japan , Asago, Japan , Asahikawa, Japan , Chita, Japan , Chiyoda-ku, Japan , Daisen, Japan , Fujioka, Japan , Fukui-shi, Japan , Fukuoka, Japan and 44 more locations